M: Thank you very much Rory. At ten o'clock this morning, Sarah Marshall began proceedings and I'm here to represent the other funder, the Medical Research Council who with the Wellcome Trust has provided core support to UK Biobank for well over a decade now. I feel rather like a bookend actually, propping up a library that's growing almost as we speak bulging at the seams. What I'd like to do is conclude with one last data slide if you'll forgive me. It's been a data rich day, but I think it illustrates an interesting and important point. What it shows, for those of you at the back, is the growth of publications from 2005 through to the present day to just short of a thousand different papers that have been published describing scientific findings, fascinating insights in biology and clinical medicine, some of which we've heard this afternoon.

What it also shows you in diagrammatic form is an estimation of the core funding that's come from the Wellcome Trust and the MRC over that same period of time, racking up to just short of 300 million pounds. The reason why I'm showing this slide to you is to illustrate the lag. An extraordinary lag of nearly a decade from the initial funding injection to the point at which we're seeing outcomes from this investment and this to me illustrates something that happened long before I became involved. It illustrates to me the vision of some of the investigators that you've heard speak today. It illustrates the conviction and the courage actually for the funders to support something which was not going to deliver a return over a short period of time. This wouldn't have worked with traditional response mode funding. We've learnt from this and because of that we've worked in a different way through UKRI and the Medical Research Council and the Office of Life Sciences to think about how we might look to the future and invest to create an advanced detection of disease cohort that you heard about from John Bell this morning. We need to be patient to see the outcome.

So finally, I'd just like to conclude the event by thanking the chairs, the speakers. It's been fascinating for me to hear about many of the new initiatives, the new discoveries, but we should all thank the half a million people who have given up their time free of charge to become participants in the UK Biobank adventure, if I can call it that, many of whom are still engaged and involved in ongoing studies such as the imaging that Paul Matthews described to us just a few minutes ago. I sense actually that we're only just at the beginning. This looks like a very impressive exponential curve. I think we're at the beginning of this journey of discovery and I for one am looking forward to the next 12 months to see what new exciting findings are going to emerge before our next annual meeting. Thank you very much.

[Applause]